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Stepped care, 
progressing from 
conservative 
measures to 
corticosteroid 
injections to 
surgery if 
necessary, seems 
reasonable.
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 What is the best way to treat 
Morton’s neuroma?
 no single treatment has been
 identified in the literature. Th at 
said, a protocol of stepped care that showed 
good results in an uncontrolled trial seems 
reasonable: patient education and foot-
wear or insole changes, followed by cor-
ticosteroid injections and, fi nally, surgery 
(strength of recommendation [SOR]: C, case 
series).
Injecting sclerosing alcohol depends 
on the provider’s access to and comfort 
with ultrasound, but the evidence is insuf-
fi cient to recommend it routinely (SOR: C, 
case series).
Evidence summary
Options for treating Morton’s neuroma in-
clude changing shoe type, using insoles or 
metatarsal pads, taking nonsteroidal anti-
infl ammatory drugs (NSAIDs), giving cor-
ticosteroid or sclerosing alcohol injections, 
and surgically excising or transposing the of-
fending nerve.1-3
Different conservative measures 
produce similar results
A small randomized prospective study of 
23 patients compared reduction in neuroma 
pain using supinatory or pronatory insoles.4 
No explicit inclusion or exclusion criteria 
other than clinical diagnosis were men-
tioned. Neither participants nor evaluators 
were blind to intervention allocations. 
Two patients (13%) dropped out at 
1 month. At 12 months, pain reduction in the su-
pination and pronation insole groups was 50% 
and 45%, respectively (not signifi cant). 
Injections improve symptoms 
with minimal adverse effects
A prospective randomized study of 82 pa-
tients compared steroid injections alone with 
shoe modifi cations.5 Primary outcomes were 
patient satisfaction (presence or absence of 
pain), amount of pain, and return of pain. 
Steroid injections yielded better pa-
tient satisfaction compared with shoe 
modifi cations alone at 1 and 6 months. 
Twenty-three percent of shoe-modifi cation 
patients achieved complete satisfaction at 
1 month, compared with 50% of injection 
patients (P<.01; number needed to treat 
[NNT]=3.7). At 6 months, the results were 
28.6% satisfaction with shoe modifi cation 
and 73.5% satisfaction with injection (P<.001; 
NNT=2.3). 
Th e diff erence disappeared at 1 year 
(63% satisfaction with shoe modifi cation 
compared with 82% satisfaction with injec-
tion; P>.05), although patients were allowed 
to cross over at 6 months. No complications 
occurred. Th e study was limited by a high 
rate of crossover from the shoe modifi cation 
to the injection group at 6 months, elimina-
tion of dropouts from the fi nal analysis, and 
lack of intent-to-treat analysis.
Another technique uses the scleros-
ing eff ects of alcohol6 delivered by multiple 
ultrasound-guided injections over time.7,8 
Improvement of symptoms with no long-
term adverse events were reported in several 
case series, although in each study a small 
number of patients reported localized pain 
at the site of injection.6-10 Th e TABLE summa-
rizes injection studies.5-11
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Surgery: 
Consider cost and risk of complications
Most surgical studies enrolled patients who 
had initially failed conservative treatments. 
Costs and risks of complications must be 
weighed, including infection, scar sensitiv-
ity, residual pain, sensory defi cits, and other 
wound-related morbidities.
Technique varies considerably among 
surgeons.12 A Cochrane systematic review of 
3 randomized controlled trials comprising 
121 patients concluded that, at most, very lim-
ited evidence exists that transposition of the 
transected plantar digital nerve may yield bet-
ter long-term results than standard resection.3 
In a retrospective case series, 82 patients 
with primary Morton’s neuroma were treated 
by a single surgeon and a single technique 
(dorsal incision and nerve transection).13 
All patients had failed conservative man-
agement with orthotics, shoe modifi cation, 
and NSAIDs (lidocaine injections were used 
only to pinpoint neuroma location). Sixty-six 
(81%) returned for follow-up.
Average follow-up evaluation was 
5.8 years. Of the patients who were followed, 
85% rated overall satisfaction as excellent or 
good. 
Stepped care gets results
A prospective case series enrolled 115 sub-
jects out of 340 consecutive patients who pre-
sented to a private orthopedic clinic with a 
diagnosis of Morton’s neuroma.1 Th e authors 
assessed a 3-stage protocol of stepped care, 
progressing to the next stage if improvement 
was inadequate after 3 months: Stage I com-
prised patient education, footwear modifi ca-
tions, and a metatarsal pad placed proximal 
to the involved nerve; stage II, injection of 
TABLE 1
How injection therapies for Morton’s neuroma compare
Study
Injection 
materials Type of study
Number of 
cases
Average 
follow-up, 
(mo)
Average 
number of 
injections Results
Greenfi eld 
19849
Steroid Retrospective case 
series
67 24 3 80% complete relief
Saygi 20055 Steroid Prospective 
quasirandomized 
injection vs 
footwear 
modifi cation
82 12 2-3 82% vs 63% complete 
or partial pain relief in 
2 groups, respectively
Markovic 200811 Steroid* Prospective 
case series
39 9 1 38% complete satisfaction 
and 28% satisfaction with 
minor reservations
Dockery 19996 Alcohol Prospective 
case series
100 13 5.5 89% resolution or 
improved symptoms
Fanucci 20048 Alcohol* Prospective 
case series
40 10 4 90% resolution or 
improved symptoms
Hughes 20077 Alcohol* Prospective 
case series
101 21.1 4.1 94% resolution or 
improved symptoms
Mozena 200710 Alcohol Retrospective 
case series
42 11 3-7 61% resolution or 
improved symptoms.
Patients with ≥5 injections 
(74%) were more likely 
to respond (P=.0072)
*Ultrasound guided.
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References
steroids with local anesthetic or local anes-
thetic alone; and stage III, surgery. 
Of 57 patients treated only with footwear 
modifi cations, 47 (41%) improved and re-
quired no further treatment. Twenty-seven 
(47%) of the 58 patients who received injec-
tions improved and required no further treat-
ment. Of the 24 patients who advanced to 
stage III, 96% improved with surgery.
Recommendations
No consensus exists regarding defi nitive 
treatment of Morton’s neuroma. Th e Ameri-
can College of Occupational and Environ-
mental Medicine recommends excision 
of the neuroma if nonsurgical treatment 
fails.14
A 2003 Cochrane systematic review of 
107 studies found insuffi  cient evidence to as-
sess effi  cacy of surgical and nonsurgical in-
terventions.3 Stepped care has been adopted 
by many third-party payers who require con-
servative care before reimbursing for injec-
tions, and treatment with injections before 
reimbursing for surgery.                 JFP
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As many as 2 million Americans are infected with 
hepatitis B and 5 million are infected with hepatitis C. Despite 
this large patient population, standards for virus prevention, 
screening, and clinical care are currently inadequate, resulting in 
a major unmet medical need. 
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